{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-034819","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.238450+00:00","generated_at":"2026-05-16T20:43:57.971850+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ImmuCell Q3 product sales $5.5M (-8% YoY); net loss narrows to $140k; gross margin recovers to 43%","bullets":["Product sales Q3 2025: $5.5M, down 8% YoY; nine-month 2025: $20.0M, up 7% YoY.","Net loss Q3 2025: ($140k) or ($0.02)/share vs ($702k) loss in Q3 2024.","Net income nine-month 2025: $1.8M ($0.20 diluted) vs ($2.7M) loss in prior period.","Gross margin improved to 43% Q3 2025 vs 26% Q3 2024; nine-month 42.6% vs 27.3%.","Adjusted EBITDA Q3: $751k vs $196k; nine-month: $4.4M vs $35k; cash $3.9M, no debt drawn."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-034819","json":"https://secwatch.observer/filing/0001437749-25-034819.json","markdown":"https://secwatch.observer/filing/0001437749-25-034819.md","text":"https://secwatch.observer/filing/0001437749-25-034819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000143774925034819/0001437749-25-034819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000143774925034819/iccc20251113_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:43:57.971850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}